– USA, MA – Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical-stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today announced the appointments Ph.D.Dr. Gary Nabel (MD, PhD), Joe Papa, and Renee Gaeta to its Board of Directors, effective August 8, 2022, replacing Dr. Alan Smith, Dr. Shaan Ghandi, and Dr. Udi Meirav.
“Innovation is central to Candel and we welcome the novel and diverse perspectives that Gary, Joe, and Renee will bring. They join the Board at an exciting time, and we look forward to working with them to further grow the company and develop life-improving oncolytic viral immunotherapies.” said Board Chairman, Paul Manning.
Dr. Paul Peter Tak, CEO, added, “We are pleased to welcome Renee, Gary, and Joseph, preeminent leaders in their respective fields, as new directors to the Candel Board. They bring a wealth of experience in the biopharmaceutical industry, science, and value creation. Each of them will offer unique and valuable perspectives that we confidently believe will add to our growth, strengthening our foundation as we pursue highly differentiated oncolytic viral immunotherapies for patients with cancer.”
About Dr. Gary Nabel
Dr. Gary Nabel, a renowned virologist, and immunologist, currently serves as CIO of OPKO and President and CEO of ModeX Therapeutics which merged as a subsidiary of OPKO Health in May 2022. Before this, he served as CSO and SVP at Sanofi, where he oversaw the Breakthrough Laboratory that worked to create the first trispecific antibodies for HIV, cancer immunotherapies, and novel vaccines. Before Sanofi, Dr. Nabel spearheaded progressive research on HIV, influenza, SARS, Ebola, Chikungunya, and Epstein-Barr virus while he served as a founding director at the NIH’s Vaccine Center for more than a decade. His honors include being elected to the Institute of Medicine for the National Academy of Science and the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, following his countless accomplishments across virology, immunology, and gene therapy, and molecular biology.
About Joseph C. Papa
Joseph Papa has more than 35 years of experience in the pharmaceutical, health care, and specialty pharmaceutical industries, including more than 20 years of the branded prescription drug experience. In July 2022, he stepped down as chair of Bausch + Lomb’s Board and will remain CEO until his successor is appointed. Before Bausch + Lomb, Mr. Papa had led various organizations, including Bausch Health formerly known as Valeant Pharmaceuticals, Perrigo, and the Cardinal Health PTS business, as Chairman and CEO separately for two decades. In 2014, he was ranked 47 on Harvard Business Review’s “Best Performing CEOs in the World”. His track record for leadership continued as he served as President and COO for Watson Pharmaceuticals (2001-2004), President of Global Country Operations for Pharmacia’s North American business (2000-2001), and President of Searle’s US Operations (1997-2000). During his 15-year career at Novartis Pharmaceuticals, he and his teams successfully launched the pharmaceutical products Lotrel®, Divovan®, and Celebrex. Mr. Papa currently serves on the Board of Prometheus Biosciences and had been a previous member of the Boards for the UConn Foundation and Smith & Nephew.
About Renee Gaeta
Renee Gaeta currently serves as CFO at Eko Devices, a privately held cardiopulmonary digital health company. Before joining Eko, she served as CFO and member of the executive team at Establishment Labs Holdings, Inc. There, she successfully led the organization to an Initial Public Offering and through a significant growth and value creation stage. Mrs. Gaeta has played integral roles across the financial sector including during her role as VP, Corporate Controller, and executive team member at publicly traded company, Sientra, Inc., where she guided the company during its pre-IPO period, as well as continued financing following their IPO. Before leading the finance department of Sientra, she excelled in multiple roles within KPMG for over a decade with her most recent role has been Advisory Director in the Transactions and Restructuring Group. Mrs. Gaeta currently serves on the Board of SeaSpine Holdings Corporation as Audit Committee Chair and is a Certified Public Accountant in the State of California.
About Candel Therapeutics
Candel is a late clinical-stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. Discovery programs are based on the enLIGHTEN HSV platform.
For more information: https://www.candeltx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.